Lv11
38 积分 2025-06-11 加入
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment
1小时前
待确认
Adverse Event Classification: Clarification and Validation of the Society of Interventional Radiology Specialty-Specific System
11天前
已完结
A phase II study of anlotinib in the first-line treatment of locally advanced or metastatic soft tissue sarcoma
1个月前
已完结
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
1个月前
已完结
The Role of Radiotherapy for Sarcoma
1个月前
已完结
Immune and Cell Cycle Checkpoint Inhibitors for Cancer Immunotherapy
1个月前
已完结
Interventional therapy for hepatocellular carcinoma in the immunotherapy era: From mechanism exploration to materials innovation
1个月前
已完结
Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria
2个月前
已完结
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy
2个月前
已完结
Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial
2个月前
已完结
皖公网安备34019202002308
